Narrator Verle was lucky. Out of 100 Emory Eye Center applicants, he was one of five chosen for a clinical trial of Lucentis, a new drug just approved by the FDA to treat the wet form of the disease.

Assistant U.S. Attorney Roger Stefin claimed some of Melgen's patients developed serious eye infections from unnecessary Lucentis injections administered on the basis of bogus macular degeneration ...

DME is often caused by the swelling of the macula, which is the center of the eye. This swelling can be ... original version of ranibizumab (Lucentis). This new FDA approval for the implant ...

Study of Lucentis (Ranibizumab ... in a response comparable with monthly intravitreal (inside the back of the eye) injections of anti-VEGF (ranibizumab) treatments. "The PDS was found to be ...

that gives patients an alternative to regular injections into the eye. Susvimo has the same active ingredient as Roche's big-selling therapy Lucentis (ranibizumab), a VEGF inhibitor administered ...

The port delivery system (PDS) formulation of ranibizumab – a VEGF inhibitor already approved as Lucentis to treat wet AMD – was able to extend the time between treatments for six months or ...

Ranibizumab (Lucentis) / bevacizumab (Avastin): Both of ... They can include traumatic cataract, detached retina, increased eye pressure, and inflammation in the eye. Pegaptanib (Macugen ...

In the Lucentis Phase III clinical trials, the most common ocular side effects included conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure. The most common ...

Background: To identify differences between Ranibizumab and Aflibercept in treatment-naïve patients with neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting ...